InCred Sets ₹2,821 Target on Mankind Pharma, Implying ~11% Upside

Indian brokerage InCred issues a modest bullish price target on large-cap Mankind Pharma from ~₹2,541, but offers no earnings forecasts, valuation methodology, or catalysts to support the call.

ndtv-profit-business · 7/7/2026, 4:31:31 AM · Ask about this →